Hypoxia-inducible factor-2 is a novel regulator of aberrant CXCL12 expression in multiple myeloma plasma cells

Sally K. Martin, Peter Diamond, Sharon A. Williams, Luen Bik To, Daniel J. Peet, Nobutaka Fujii, Stan Gronthos, Adrian L. Harris, and Andrew C.W. Zannettino

Myeloma Research Program, Division of Haematology, Centre for Cancer Biology–SA Pathology and University of Adelaide, Australia; Department of Molecular Bioscience, University of Adelaide, Australia; Department of Bioorganic Medicinal Chemistry, Graduate School of Pharmaceutical Sciences, Kyoto University, Japan; Mesenchymal Stem Cell Group, Division of Haematology, Hanson Institute, CSCR and University of Adelaide, Australia, and Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, UK


Online Supplementary Figure S1. Hypoxic regulation of CXCL12 expression in human MM cell lines. Levels of CXCL12 mRNA expression were measured in U266, RPMI-8226, JIMI and LP-1 MM plasma cell lines following 6, 24 and 48 h of normoxic (white bars) or hypoxic (black bars) culture. Columns, mean (n=3); bars, SEM. *p<0.05, **p<0.005.
Online Supplementary Figure S2. Hypoxic regulation of CXCL12, GLUT1, CXCR4 and VEGF expression in LP-1 cells. CXCL12, GLUT1, CXCR4 and VEGF mRNA expression was measured in LP-1 cells cultured under normoxic (white bars) or hypoxic (black bars) conditions for up to 72 h. Columns, mean (n=3); bars, SEM.*P<0.05, **P<0.005.
Online Supplementary Figure S3. The in vivo and in vitro growth of CXCL12-, HIF-1α and HIF-2α over-expressing LP-1 cells. (A) CXCL12-, HIF-1α or HIF-2α-over-expressing LP-1 cells were injected subcutaneously in a Matrigel plug into mice (n=12/group), and half of the mice were administered the CXCR4 antagonist, T140. Tumor growth was monitored weekly for 2 weeks using bioluminescence imaging. (B) The rate of in vitro proliferation of CXCL12-, HIF-1α or HIF-2α over-expressing LP-1 cells was assessed using WST-1. Lines, mean (n=4). P>0.05 (NS).